NCT00800345View on ClinicalTrials.gov

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

June 30, 2015

Study Completion Date

September 30, 2015

Conditions
Gynecologic Tumors
Interventions
DRUG

Oral Topotecan

Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.

DRUG

Pazopanib

Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.

Trial Locations (1)

38120

The West Clinic, Memphis

Sponsors

Lead Sponsor

Vector Oncology

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Vector Oncology

OTHER

NCT00800345 - Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors | Biotech Hunter | Biotech Hunter